Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 23;16(9):e0257817.
doi: 10.1371/journal.pone.0257817. eCollection 2021.

An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients

Affiliations

An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients

Philippe Halfon et al. PLoS One. .

Abstract

Background & aim: We investigated the combination of rapid antigen detection (RAD) and RT-qPCR assays in a stepwise procedure to optimize the detection of COVID-19.

Methods: From August 2020 to November 2020, 43,399 patients were screened in our laboratory for COVID-19 diagnostic by RT-qPCR using nasopharyngeal swab. Overall, 4,691 of the 43,399 were found to be positive, and 200 were retrieved for RAD testing allowing comparison of diagnostic accuracy between RAD and RT-qPCR. Cycle threshold (Ct) and time from symptoms onset (TSO) were included as covariates.

Results: The overall sensitivity, specificity, PPV, NPV, LR-, and LR+ of RAD compared with RT-qPCR were 72% (95%CI 62%-81%), 99% (95% CI95%-100%), 99% (95%CI 93%-100%), and 78% (95%CI 70%-85%), 0.28 (95%CI 0.21-0.39), and 72 (95%CI 10-208) respectively. Sensitivity was higher for patients with Ct ≤ 25 regardless of TSO: TSO ≤ 4 days 92% (95%CI 75%-99%), TSO > 4 days 100% (95%CI 54%-100%), and asymptomatic 100% (95%CI 78-100%). Overall, combining RAD and RT-qPCR would allow reducing from only 4% the number of RT-qPCR needed.

Conclusions: This study highlights the risk of misdiagnosing COVID-19 in 28% of patients if RAD is used alone. A stepwise analysis that combines RAD and RT-qPCR would be an efficient screening procedure for COVID-19 detection and may facilitate the control of the outbreak.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Study flowchart.
TSO, time from symptoms onset; RAD, rapid antigen detection.
Fig 2
Fig 2. Ct values according to time from symptoms onset, and sensitivities of rapid antigen detection assay according to Ct and time from symptoms onset.
TSO, time from symptoms onset.
Fig 3
Fig 3. Stepwise algorithm combining rapid antigen detection and RT-qPCR.
PPV, positive predictive value; NPV, negative predictive value; LR-, negative likelihood ratio; LR+, positive likelihood ratio.

References

    1. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity—A Strategy for Containment. N Engl J Med. 2020. doi: 10.1056/NEJMp2025631 - DOI - PubMed
    1. Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H, et al.. SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations. Anal Bioanal Chem. 2020. doi: 10.1007/s00216-020-02958-1 - DOI - PMC - PubMed
    1. He D, Zhao S, Lin Q, Zhuang Z, Cao P, Wang MH, et al.. The relative transmissibility of asymptomatic COVID-19 infections among close contacts. International Journal of Infectious Diseases. 2020;94: 145–147. doi: 10.1016/j.ijid.2020.04.034 - DOI - PMC - PubMed
    1. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581: 465–469. doi: 10.1038/s41586-020-2196-x - DOI - PubMed
    1. Cerutti F, Burdino E, Milia MG, Allice T, Gregori G, Bruzzone B, et al.. Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2. Journal of Clinical Virology. 2020;132: 104654. doi: 10.1016/j.jcv.2020.104654 - DOI - PMC - PubMed

Substances